散发性甲状腺髓样癌生化不完全缓解患者的临床演变
该研究纳入599例2000至2018年在比萨大学医院接受手术并随访的散发性甲状腺髓样癌患者,术后中位5个月时145例(24.2%)为生化不完全缓解(BiR),其中64例(44.1%)在中位3.3年后检出结构性疾病,10年检出风险约50%;基線降钙素(bCTN)和IVa/b期是独立预测因素,CTN倍增时间短和体细胞RET突变者结构性疾病更常见。
要点
- 散发性MTC术后BiR患者10年内结构性疾病检出风险约50%。
- bCTN升高和IVa/b期是结构性疾病检出的独立预测因素。
- CTN倍增时间短和体细胞RET突变者结构性疾病更常见。
核心结论
- 散发性MTC伴BiR患者结构性疾病检出风险10年约50%。
- 较高的bCTN水平和分期预测结构性疾病检出风险。
- 作者认为对BiR伴bCTN升高和晚期患者应更严格随访,所有BiR患者应考虑长期随访。
研究设计与样本
- 评估599例2000至2018年在比萨大学医院内分泌科手术并随访的散发性MTC连续患者数据。
主要发现
- 术后中位5个月,599例中145例(24.2%)分类为BiR。
- 145例BiR中64例(44.1%)在中位3.3年后检出结构性疾病。
- 73.6%的结构性疾病为单一部位,以颈部淋巴结为主。
- 术后首次评估时,仅bCTN和IVa/b期为独立预测因素。
- CTN倍增时间短和体细胞RET突变的患者结构性疾病更常见。
关键数值与推荐
- BiR定义为术后中位5个月分类,结构性疾病检出风险10年约50%。
临床怎么用
- 作者认为对BiR伴bCTN升高和晚期患者应更严格随访。
- 作者认为所有BiR患者应考虑长期随访,因50%在10年内发生结构性疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The clinical response after surgery is a determinant in the management of patients with medullary thyroid carcinoma (MTC). In case of excellent or structural incomplete response, the follow-up strategies are well designed. Conversely, in case of biochemical incomplete response (BiR) the management is not clearly defined. OBJECTIVE: This work aimed to evaluate the overall and per-site prevalence of structural disease detection in sporadic MTC patients with BiR and to assess the predictive value of various clinical, biochemical, and genetic features. METHODS: We evaluated data of 599 consecutive patients surgically treated for sporadic MTC (2000-2018) and followed-up at the endocrine unit of the University Hospital of Pisa. RESULTS: After a median of 5 months from surgery, 145 of 599 (24.2%) patients were classified as BiR. Structural disease was detected in 64 of 145 (44.1%), after a median time of 3.3 years. In 73.6%, structural disease was detected at a single site, prevalently cervical lymph nodes. Among several others, at the time of first evaluation after surgery, only basal calcitonin (bCTN) and stage IVa/b were independent predictive factors. Also, structural disease was more frequent in patients with shorter CTN doubling time and somatic RET mutation. CONCLUSION: In sporadic MTC patients with BiR, the risk of detection of structural disease was about 50% at 10 years. Higher bCTN levels and staging predicted the risk of detecting structural disease. According to these findings, stricter follow-up should be reserved for MTC with BiR and elevated values of bCTN and to those with an advanced stage. Long follow-up should be considered for all BiR patients since 50% of them develop structural disease within 10 years.
引用
- Prete A, Gambale C, Torregrossa L, et al. Clinical Evolution of Sporadic Medullary Thyroid Carcinoma With Biochemical Incomplete Response After Initial Treatment. J Clin Endocrinol Metab. 2023. PMID: 36722192. doi:10.1210/clinem/dgad061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。